Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma

Summary

This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy. Patients must have received in prior therapy either bortezomib or lenalidomide

Timeline

Start

2007-04-16

Primary completion

2008-05-19

Completion

2009-12-25

Drugs

Indications